<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - CERTOLIZUMAB PEGOL</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>CERTOLIZUMAB PEGOL</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#patientAndCarerAdvice" data-toggle="tab">Patient and carer advice</a></li>
          <li><a href="#nationalFunding" data-toggle="tab">National funding/access decisions</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#conceptionAndContraception" data-toggle="tab">conception and contraception</a></li>
          <li><a href="#monitoringRequirements" data-toggle="tab">Monitoring requirements</a></li>
          <li><a href="#preTreatmentScreening" data-toggle="tab">Pre-treatment screening</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Moderate to severe active rheumatoid arthritis when response to disease-modifying antirheumatic drugs (including methotrexate) has been inadequate (as monotherapy or in combination with methotrexate)</span>,
            </h4>
            <p class="specificity"><span class="route">By subcutaneous injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                400 mg every 2 weeks for 3 doses, then 200 mg every 2 weeks, review treatment if no response within 12 weeks.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Treatment of severe active ankylosing spondylitis in patients who have had an inadequate response to, or are intolerant of NSAIDs</span>,
                <span class="indication">Treatment of severe active axial spondyloarthritis, without radiographic evidence of ankylosing spondylitis but with objective signs of inflammation, in patients who have had an inadequate response to, or are intolerant of NSAIDs</span>,
            </h4>
            <p class="specificity"><span class="route">By subcutaneous injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                400 mg every 2 weeks for 3 doses, then 200 mg every 2 weeks, alternatively 400 mg every 4 weeks, review treatment if no response within 12 weeks.</li>
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>



      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>Avoid.</p>
            </section>
      </section>



      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

          <ul>
            <li>Moderate to severe heart failure</li>
            <li>severe active infection</li>
          </ul>
      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> Hypertension, rash, sensory abnormalities,
              </p>
              <p>
                <strong>uncommon:</strong> Acne, alopecia, anxiety, appetite disorders, arrhythmias, ascites, asthma, benign tumours, cardiomyopathies, cholestasis, cough, dermatitis, dizziness, dyslipidaemia, ecchymosis, electrolyte disorders, gastro-intestinal disorders, gastro-intestinal perforation, gastro-intestinal ulcer, haematuria, haemorrhage, heart failure, hepatic disorders, impaired healing, influenza-like illness, ischaemic coronary artery disorders, leukaemia, lymphoma, malignancy, menstrual disorders, mood disorders, muscle disorders, nail disorders, new onset or worsening psoriasis, ocular inflammation, oedema, peripheral neuropathy, photosensitivity, pleural effusion, renal impairment, skin cancer, skin discoloration, solid tumours, syncope, tinnitus, tremor, visual disturbance,
              </p>
              <p>
                <strong>rare:</strong> Atrioventricular block, cerebrovascular accident, cholelithiasis, impaired coordination, interstitial lung disease, nephropathy, Raynaud&#8217;s phenomenon, seizures, sexual dysfunction, splenomegaly, thyroid disorders, trigeminal neuralgia,
              </p>
              <p>
                <strong>notKnown:</strong> Abdominal pain, anaemia, antibody formation, aplastic anaemia, blood disorders, depression, fever, headache, hypersensitivity reactions, infections, injection-site reactions, leucopenia, lupus erythematosus-like syndrome, multiple sclerosis, nausea, pancytopenia, pruritus, thrombocytopenia, worsening heart failure,
              </p>
        
        
            <section class="advice">
                <h3>Infection</h3>
              <p>Associated with infections, sometimes severe, including tuberculosis, septicaemia, and hepatitis B reactivation.</p>
            </section>
        
      </section>


      <section class="tab-pane" id="patientAndCarerAdvice">
        <h2>Advice for patients and carers</h2>

            <section class="generalPatientAdvice">
                <h3>Blood disorders</h3>
              <p>Patients should be advised to seek medical attention if symptoms suggestive of blood disorders (such as fever, sore throat, bruising, or bleeding) develop.</p>
            </section>
            <section class="generalPatientAdvice">
                <h3>Tuberculosis</h3>
              <p>Patients should be advised to seek medical attention if symptoms suggestive of tuberculosis (e.g persistent cough, weight loss and fever) develop.</p>
            </section>
            <section class="patientResources">
              <p>An alert card should be provided.</p>
            </section>
      </section>

      <section class="tab-pane" id="nationalFunding">
        <h2>National funding/access decisions</h2>

            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA186</h3>
              <p outputclass="title">Certolizumab pegol for the treatment of rheumatoid arthritis (February 2010)</p> <p>Certolizumab pegol is an option for the treatment of patients with rheumatoid arthritis only if:</p> <ul> <li>certolizumab pegol is used as described in the NICE guidance (October 2007) for other tumour necrosis factor (TNF) inhibitors (see Adalimumab, Etanercept and Infliximab for the treatment of Rheumatoid Arthritis), <i>and</i> </li> <li>the manufacturer provides the first 12 weeks of certolizumab pegol (10 prefilled 200-mg syringes) free of charge to all patients starting treatment.</li> </ul><xref format="html" href="http://www.nice.org.uk/TA186">www.nice.org.uk/TA186</xref>
                <a href="http://www.nice.org.uk/TA186" target="_blank">www.nice.org.uk/TA186</a>
            </section>
      </section>


      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Demyelinating CNS disorders (risk of exacerbation)
          </li>
          <li>
            do not initiate until active infections are controlled (discontinue if new serious infection develops and until infection controlled)
          </li>
          <li>
            hepatitis B virus (monitor for active infection)
          </li>
          <li>
            history or development of malignancy
          </li>
          <li>
            mild heart failure (discontinue if symptoms develop or worsen)
          </li>
          <li>
            predisposition to infection
          </li>
        </ul>
        <ul>
          <li>
            <p>Active tuberculosis should be treated with standard treatment for at least 2 months before starting certolizumab pegol. Patients who have previously received adequate treatment for tuberculosis can start certolizumab pegol but should be monitored every 3 months for possible recurrence. In patients without active tuberculosis but who were previously not treated adequately, chemoprophylaxis should ideally be completed before starting certolizumab pegol. In patients at high risk of tuberculosis who cannot be assessed by tuberculin skin test, chemoprophylaxis can be given concurrently with certolizumab pegol.</p>
          </li>
        </ul>
      </section>

      <section class="tab-pane" id="conceptionAndContraception">
        <h2>Advice regarding conception and contraception</h2>

            <section class="generalInformation">
              <p>Manufacturer advises adequate contraception during treatment and for at least 5 months after last dose.</p>
            </section>
      </section>

      <section class="tab-pane" id="monitoringRequirements">
        <h2>Monitoring requirements</h2>

        
          <h3>Patient parameters</h3>
        
            <section class="patientParameters">
              <p>Monitor for infection before, during, and for 5 months after treatment.</p>
            </section>
      </section>






      <section class="tab-pane" id="preTreatmentScreening">
        <h2>Pre-treatment screening</h2>

            <section class="preTreatmentScreening">
                <h3>Tuberculosis</h3>
              <p>Patients should be evaluated for tuberculosis before treatment.</p>
            </section>
      </section>





      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of CERTOLIZUMAB PEGOL</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        

            <div id="PHP76745"><a href="../medicinalForm/PHP76745.html" data-target="#PHP76745" data-action="load">Solution for injection</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
